Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
Completed · Phase 2
Conditions studied: Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
In brief
This is a two-cohort, multicenter, open-label study of tafasitamab (MOR208) combined with idelalisib or venetoclax in adult patients with R/R CLL or R/R SLL pretreated with a BTK inhibitor (e.g., ibrutinib) as single agent or as part of combination therapy. Patients completing the study treatment are invited to participate in an optional biomarker sub-study.
Key facts
- Study ID
- NCT02639910
- Run by
- MorphoSys AG
- People needed
- 24
- Starts
- 2016-11-01
- Expected to finish
- 2021-12-01
- Last updated by the study team
- 2021-12-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Study Site — Jacksonville, Florida, United States
- Clinical Study Site — Rochester, Minnesota, United States
- Clinical Study Site — Columbus, Ohio, United States
- Clinical Study Site — Graz, Austria
- Clinical Study Site — Salzburg, Austria
- Clinical Study Site — Vienna, Austria
- Clinical Study Site — Dresden, Germany
- Clinical Study Site — Leipzig, Germany
- Clinical Study Site — München, Germany
- Clinical Study Site — Brescia, Italy
- Clinical Study Site — Milan, Italy
- Clinical Study Site — Gdansk, Poland
- Clinical Study Site — Krakow, Poland
- Clinical Study Site — Lublin, Poland
- Clinical Study Site — Opole, Poland
- Clinical Study Site — Bournemouth, United Kingdom
- Clinical Study Site — Leeds, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.